The research, published in the journal Diabetes, Obesity and Metabolism, suggests that the injectable GLP-1 drugs may make ...

Patients should always consult a qualified healthcare professional before starting any weight loss drug and avoid ...

“Currently, less than 2% of individuals with obesity in the U.S. receive obesity medication and Wegovy in a pill may also ...

Novo Nordisk's diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world study of certain U.S. patients ...

Novo Nordisk A/S is a strong buy for 2024, with cutting-edge drug approvals, cost savings, and robust long-term growth potential. Click for my NVO stock update.

Tirzepatide offers more favorable return on investment, but greater benefits seen at lower costs for Roux-en-Y gastric bypass ...

Makers of GLP-1 drugs, including Novo Nordisk, Eli Lilly and others, are close to releasing daily pills to help shed pounds ...

Wegovy has been a hugely popular treatment since the Food and Drug Administration (FDA) approved it for weight loss in ...

Omada Health (OMDA) remains a buy, driven by accelerating membership growth, multi-condition adoption, and a massive ...

The "Bridesmaids" actor shares her "go-to" meal that includes protein and some vegetables that helps her navigate maintenance ...

Weight-loss medications reduced body weight in children and teens, but the sample size was too small to make conclusions ...